What is NDC 68727-950?

68727-950 is the product NDC for Ziihera (zanidatamab-hrii), Zanidatamab 50 mg/mL injection, powder, lyophilized, for solution, listed with the FDA by Jazz Pharmaceuticals, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Jazz Pharmaceuticals, Inc., NDC labeler code 68727. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Ziihera?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Ziihera NDC 68727-950 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)68727-950Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68727-0950Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68727-950-02	68727095002	2 VIAL, SINGLE-DOSE in 1 CARTON (68727-950-02) / 6 mL in 1 VIAL, SINGLE-DOSE (68727-950-01)Marketed from Nov 20, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ziihera
Generic name (nonproprietary): zanidatamab-hrii
Active ingredients: Zanidatamab — 50 mg/mL
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous
Labeler: Jazz Pharmaceuticals, Inc.NDC labeler code 68727
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761416
Marketing start: Nov 20, 2024
Listing expires: Dec 31, 2027
Other FDA classes: HER2-directed Antibody Interactions (Mechanism)
Identifiers: Product ID 68727-950_526942b1-adcb-4202-82ab-3d5eaaefc812SPL ID 526942b1-adcb-4202-82ab-3d5eaaefc812SPL set ID ae5d9425-fae5-4541-a158-150998343348RxCUI 2698206, 2698212UNII Z20OC92TDI
Pharmacologic class: Bispecific HER2-directed Antibody

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N468727095002 followed by a unit qualifier and the quantity

Package 68727-0950-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 24, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

ZIIHERA is a bispecific HER2-directed antibody indicated for: Gastroesophageal Adenocarcinoma (GEA) • in combination with fluoropyrimidine- and platinum-containing chemotherapy, and tislelizumab-jsgr, as first-line treatment of adult patients with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-authorized test. ( 1.1 ) • in combination with fluoropyrimidine- and platinum-containing chemotherapy, as first-line treatment of adult patients with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma,…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 68727-950

What is NDC 68727-950?: 68727-950 is the product NDC for Ziihera (zanidatamab-hrii), Zanidatamab 50 mg/mL injection, powder, lyophilized, for solution, listed with the FDA by Jazz Pharmaceuticals, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Ziihera (Zanidatamab-hrii).
What is the active ingredient?: Zanidatamab.
Who is the labeler?: Jazz Pharmaceuticals, Inc., NDC labeler code 68727. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Ziihera?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Ziihera (Zanidatamab-hrii) NDC 68727-950